Benzoyl peroxide
An acne treatment and antibiotic-regimen partner that also appears in a distinct approved rosacea formulation. Concentration alone cannot make different vehicles and indications interchangeable.
The marker is a representative concentration from the cited records. The bar includes approved and compounded preparations recorded here. It is not a recommended dose, a minimum effective strength or a claim that other concentrations are untested. Evidence depends on the vehicle, indication and trial population.
The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.
An oxidising agent with bactericidal and keratolytic effects. It does not select for bacterial resistance, which is why it is conventionally paired with topical antibiotics. The label of the approved rosacea product states that the precise mechanism in rosacea is unknown.
If a compounded acne prescription includes clindamycin, ask the clinician how benzoyl peroxide and the antibiotic's duration are handled. The absence of benzoyl peroxide from one bottle does not establish that it is absent from the treatment plan. Its inclusion also does not remove the need for reassessment.
CABTREO and TWYNEO offer defined acne combinations. The existing EPSOLAY review concerns rosacea. Do not compare their trial success rates as though all participants had the same condition, or replace one vehicle with another solely because the active name matches.
Ask about the actual prescribed products and whether a separate cleanser or active duplicates a component. The clinical plan should identify the application area, timing and response to irritation. Our product reviews assess public documentation, without personal tolerance testing.
Guideline summary recommends combining mechanisms and using benzoyl peroxide with topical or oral antibiotics to reduce resistance. Checked 13 September 2026.
Label revised March 2025: exact strengths, acne indication, two vehicle-controlled trials, contraindications and ten-week dispensing expiration. Checked 13 September 2026.
February 2025 label names Mayne Pharma and a 30 g pump. Trial 1 success and difference figures in Table 4 conflict; that row is not charted here. Storage limits are product-specific. Checked 13 September 2026.
One reader gets a 12 months CoreAge Rx derm plan — the compounded, physician-reviewed subscription we take apart in the register. Worth $780. Leave an address and you are entered.
VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.